Geron Corp financial data

Symbol
GERN on Nasdaq, GERNW on OTC
Industry
Pharmaceutical Preparations
Location
919 East Hillsdale Boulevard, Suite 250, Foster City, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
GERON CORPORATION (to 8/5/2005)
Latest financial report
Q1 2024 - May 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 383 % -5.76%
Return On Equity -68.2 % +25.4%
Return On Assets -47.3 % +14.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 593M shares +16.6%
Common Stock, Shares, Outstanding 545M shares +39.6%
Entity Public Float 1.39B USD +177%
Common Stock, Value, Issued 591K USD +16.1%
Weighted Average Number of Shares Outstanding, Basic 603M shares +10.8%
Weighted Average Number of Shares Outstanding, Diluted 603M shares +10.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 520K USD +5.26%
General and Administrative Expense 83.3M USD +67.2%
Operating Income (Loss) -210M USD -40%
Net Income (Loss) Attributable to Parent -201M USD -34.3%
Earnings Per Share, Basic -0.34 USD/shares +2.86%
Earnings Per Share, Diluted -0.34 USD/shares +2.86%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 190M USD +68.3%
Assets, Current 452M USD +16.7%
Property, Plant and Equipment, Net 1.68M USD +57.7%
Operating Lease, Right-of-Use Asset 3.39M USD -15.1%
Assets 482M USD +13.5%
Accounts Payable, Current 9.99M USD +195%
Employee-related Liabilities, Current 6.79M USD +38.5%
Accrued Liabilities, Current 33.9M USD -2.31%
Liabilities, Current 123M USD +180%
Operating Lease, Liability, Noncurrent 2.83M USD -19.4%
Liabilities 146M USD +32.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -273K USD -70.6%
Retained Earnings (Accumulated Deficit) -1.65B USD -13.9%
Stockholders' Equity Attributable to Parent 345M USD +5.77%
Liabilities and Equity 482M USD +13.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -62.3M USD -34.3%
Net Cash Provided by (Used in) Financing Activities 148M USD -47.4%
Net Cash Provided by (Used in) Investing Activities 34.2M USD
Common Stock, Shares Authorized 1.35B shares 0%
Common Stock, Shares, Issued 545M shares +39.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 120M USD +114%
Interest Paid, Excluding Capitalized Interest, Operating Activities -7.02M USD -236%
Deferred Tax Assets, Valuation Allowance 395M USD +13%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 396M USD +13%
Payments to Acquire Property, Plant, and Equipment 615K USD +65.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -202M USD -34.9%
Property, Plant and Equipment, Gross 2.41M USD +42.6%
Operating Lease, Liability, Current 955K USD +2.58%
Deferred Tax Assets, Operating Loss Carryforwards 272M USD +6.99%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 3M shares 0%
Unrecognized Tax Benefits 26.3M USD +11%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1M USD -9.09%
Share-based Payment Arrangement, Expense 20.4M USD +121%
Interest Expense 9.82M USD +34.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%